Original ArticleEarly Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma
Introduction
The dismal prognosis in patients with recurrent malignant glioma has driven interest in the development of a wide array of new therapies, including direct interstitial delivery techniques such as convection-enhanced delivery (CED). CED is a local delivery technique that bypasses the blood–brain barrier by delivering drugs through positive pressure bulk flow into the brain via stereotactically placed catheters. This method is designed to help overcome 2 major obstacles in malignant glioma therapy: 1) via bypassing the restrictive nature of the blood–brain barrier, which limits the efficacy of many promising chemotherapeutics; and 2) by virtue of regional drug delivery, CED may be better suited to address the high rate of local recurrence in malignant glioma compared with conventional intravenous chemotherapy.
One of the challenges in developing effective therapy for malignant glioma is the absence of noninvasive imaging biomarkers that can accurately determine antitumor effect early during the course of therapy. Contrast-enhanced magnetic resonance imaging (MRI) is the current key element in clinical assessment of treatment response before and after combined radiotherapy and temozolomide chemotherapy (RT/TMZ) based on the original Macdonald criteria (27) and its recent update by the Response Assessment in Neuro-Oncology Working Group (RANO) (40). Early treatment response may be transient and may not necessarily correlate with a long-term favorable outcome.
This has proven problematic in conventional and experimental treatment response assessment, because early treatment-related imaging changes manifesting as transient increases in contrast enhancement that spontaneously resolve frequently can be indistinguishable from disease progression, commonly referred to as pseudoprogression (5). Patients with pseudoprogression have a spurious increase in contrast-enhancing tumor volume weeks to months after treatment for glioma that improves spontaneously, without any changes in their treatment regimen. There is some speculation as to the responsible mechanisms, although pseudoprogression likely reflects an exaggerated response to effective therapy (9). The accurate prediction of which tumors that exhibit an increase in contrast-enhancing volume early after treatment represent progressive disease (PD) or pseudoprogression has not been established definitively by the use of noninvasive imaging techniques. Definitive diagnosis is dependent upon histology, which must be obtained through invasive procedures. It is of significant clinical interest to identify a noninvasive method of determining which tumors that appeared to be growing early after conventional or experimental therapy were truly progressing and which were exhibiting pseudoprogression and would eventually respond.
Optimal parameters for the noninvasive evaluation of early treatment response to standard or novel therapies such as CED currently are not well defined. Recent advances in multiparametric MRI may provide quantitative information that can aid in monitoring therapeutic response and potentially predict clinical outcome early in the course of therapy. Contrast-enhanced perfusion MRI may offer increased specificity regarding the tumor microenvironment before, during, and after therapy; this information is not readily available or apparent on conventional contrast-enhanced anatomic MRI.
Perfusion MRI-based techniques have demonstrated utility in the grading of gliomas 2, 21, 22, 23 and have been shown to be a prognostic marker in predicting survival after therapy 7, 24, 28. Higher-grade tumors tend to have elevated relative cerebral blood volume (rCBV), which highlights the significant role of vascular proliferation in the biology of high-grade gliomas, given the associations between tumor grade, microvessel density, and rCBV (34). Perfusion MRI can play a role in monitoring therapeutic response to either standard (28) or experimental therapies in malignant glioma. For example, changes in the volume transfer coefficient as determined by dynamic contrast-enhanced (DCE) MRI have been shown to correlate with survival even after a single dose of cediranib (33), an experimental vascular endothelial growth factor inhibitor.
The purpose of this study was to examine changes in rCBV and enhancing tumor volume parameters in patients with recurrent malignant glioma treated with CED topotecan. Our hypothesis was that changes in rCBV at 1 month after therapy would correlate with treatment response or failure as determined by 6-month progression status and thus potentially circumvent some of the clinical challenges presented by the pseudoprogression phenomenon. In this work, we used 6-month progression status as the clinical end point of efficacy, which has been endorsed by the North American Brain Tumor Coalition and used in several other studies in the evaluation of therapies for newly diagnosed or recurrent malignant glioma patients 13, 31, in addition to having been shown to be a strong predictor of survival (31).
Section snippets
Patient Population
Sixteen patients with recurrent or progressive supratentorial malignant glioma (World Health Organization grade III or IV) who underwent CED of topotecan at Columbia University Medical Center as part of a prospective Phase Ib open-label, nonrandomized trial were selected retrospectively for this Health Insurance Portability and Accountability Act-compliant Institutional Review Board–approved study. All patients in this study previously had therapy with external beam radiation, 15 of 16 patients
Cerebral Blood Volume
The mean percent change in the tumor rCBV at 1 month compared with baseline was significantly different between patients with PD and patients with NPD at 6 months (+11.9% vs. −28.9%, P = 0.02, Wilcoxon rank sum test) (see Table 2). The accuracy of rCBV in differentiating patients with PD compared with those with NPD at 6 months, as determined by the total area under the curve in ROC analysis, was classified as very good (0.8667; standard error 0.107) (See Figure 1). ROC analysis demonstrated
Discussion
In this small pilot study of patients with recurrent malignant glioma treated with 4 days of continuous CED topotecan, we found that the percent change in rCBV at 1 month after therapy was predictive of 6-month progression status, whereas the percent change in enhancing tumor volume at 1 month did not reach significance.
In evaluating experimental therapies for glioma, an accurate differentiation of patients with early PD from those with NPD is important in clinical management and to avoid a
References (42)
- et al.
Dynamic susceptibility contrast MRI of gliomas
Neuroimaging Clin N Am
(2002) - et al.
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Lancet Oncol
(2008) - et al.
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]
Int J Radiat Oncol Biol Phys
(2006) - et al.
Impact of perfusion map analysis on early survival prediction accuracy in glioma patients
Transl Oncol
(2013) - et al.
Comparison of three different mr perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease
Acad Radiol
(2013) - et al.
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings
Radiology
(1994) - et al.
Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas
Radiology
(2012) - et al.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
J Clin Oncol
(2008) - et al.
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan
Neurosurgery
(2011) - et al.
Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging
Radiology
(2002)
Pseudoprogression in glioblastoma. (letter and reply)
J Clin Oncol
Early necrosis following temodar and radiotherapy in patients with glioblastoma
J Neurooncol
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Neurology
Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients
Magn Reson Med
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
J Clin Oncol
Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol
Radiology
Pseudoprogression of glioblastoma after chemo-and radiation therapy: diagnosis by using dynamic susceptibility weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival
Radiology
The parametric response map is an imaging biomarker for early cancer treatment outcome
Nat Med
Effect of adding temozolomide to radiation therapy on the incidence of pseudoprogression
J Neurooncol
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival
Neuro-oncology
Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging
J Neurooncol
Cited by (3)
Moving toward a consensus DSC-MRI protocol: Validation of a low-flip angle single-dose option as a reference standard for brain tumors
2019, American Journal of NeuroradiologyIn vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization
2017, Drug Delivery and Translational ResearchBrain tumours
2017, Medical Radiology
Conflict of interest statement: This study was supported by National Institutes of Health grant 5RO1CA89395.